Understanding how genetic regulatory variation affects gene expression in different T cell states is essential to deciphering autoimmunity. We conducted a high-resolution RNA-seq time course analysis of stimulated memory CD4 + T cells from 24 healthy individuals. We identified 186 genes with dynamic allele-specific expression, where the balance of alleles changes over time. These genes were four fold enriched in autoimmune loci. We found pervasive dynamic regulatory effects within six HLA genes, particularly for a major autoimmune risk gene, HLA-DQB1. Each HLA-DQB1 allele had one of three distinct transcriptional regulatory programs. Using CRISPR/Cas9 genomic editing we demonstrated that a single nucleotide variant at the promoter is causal for T cell-specific control of HLA-DQB1 expression. Our study in CD4 + T cells shows that genetic variation in cis regulatory elements may affect gene expression in a lymphocyte activation status-dependent manner contributing to the inter-individual complexity of immune responses.
in germinal centers. Interestingly, gene expression changes were coordinated with allelic imbalance changes over time (Fig. 1E) . Hence, dynamic allelic imbalance suggests complex and continuous regulation during T cell activation affected by genetic variation. Consistent with this, dynASE genes were enriched for "immune response" function (P = 2.9e-09), even with respect to the genes with significant overall ASE (P = 2.5e-05, Methods).
Strikingly, we observed 182 dynASE events within the MHC locus (Fig 1C) , with 15 events in HLA-DQB1 (examples in fig. S8 , Table S1 ), which harbors most of the genetic risk for type 1 diabetes (T1D) and celiac disease (12, 13) . HLA-DQB1 is part of the HLA class II genes, that are typically expressed in antigen presenting cells, and present antigen to CD4 + T cells to coordinate immune response. In human T cells, these genes are recognized as activation markers. Their expression is well characterized in T cells from the synovial fluid and tissue of rheumatoid arthritis patients, and in blood from patients with a variety of autoimmune disorders (14) (15) (16) (17) (18) . Literature suggests that T cells themselves may also present viral and self-peptides to alter immune responses (19) (20) (21) . However, further investigation is needed to confidently establish the function of HLA class II genes in T cells.
To better understand the relationship between HLA classical alleles (a combination of multiple coding variants) and regulatory variation, we performed high resolution typing of HLA-DQB1, HLA-DRB1, HLA-DQA1, HLA-A, HLA-B, and HLA-C, for all 24 individuals in our dataset (see Methods). To robustly identify dynASE in this highly polymorphic region, we built an HLApersonalized genome for each individual ( Fig. 2A) by adding the cDNA allelic sequences for each HLA allele to the reference genome. We then quantified the number of uniquely mapped reads to each HLA allele per individual. Among the 48 HLA-DQB1 ~780bp sequences, there were 14 HLA-DQB1 4-digit classical alleles. Our unique HLA-personalized genome strategy allowed us to quantify expression of individual HLA-DQB1 alleles taking advantage of >20 SNPs in four exons (Fig. 2B, replication fig. S9 ). Our study underscores the importance of using a genotype-based personalized genome strategy to quanity cis regulatory effects within the HLA region.
Using allelic counts over the four exons of HLA-DQB1, we determined that most (15/24) individuals have significant dynASE for HLA-DQB1 (P < 0.002 = 0.05/24 tests). For example, Figure 2C depicts profiles of allelic expression levels for three individuals, with their respective allelic fraction patterns over time.
Clustering of allelic expression profiles revealed that HLA-DQB1 4-digit classical alleles clustered together more than expected by chance (permutation P < 0.001, fig. S10 ), suggesting cis regulatory effects segregate with HLA-DQB1 classical coding alleles. These allelic profiles could be grouped into three transcriptional groups (Fig. 2D , shown also with PCA on fig. S11 ). We named these three HLA-DQB1 cis regulatory programs based on their expression dynamics: Late-Spike, Constant-Low, and Fluctuating (Fig. 2D) . To our knowledge, the identification of three distinct transcriptional profiles in HLA-DQB1 expression over time is the first description of such complex and variable regulation in any gene.
To confirm that the drastic mRNA up-regulation in the Late-Spike cis regulatory program affected cell-surface protein expression levels, we isolated memory CD4 + T cells from an independent cohort. We specifically recruited five homozygous individuals for HLA-DQB1 classical alleles with the Late-Spike cis regulatory program, and five homozygous individuals for HLA-DQB1 classical alleles with Constant-Low or Fluctuating cis regulatory programs (fig. S12). As predicted, we observed that HLA-DQ cell surface expression on HLA-DQ + cells was significantly higher in individuals with the Late-Spike haplotype (P = 0.03, Wilcoxon test, Fig.  2E, fig. S13 ).
We then sought to identify the genetic variant driving the Late-Spike cis regulatory program with genetic and epigenetic fine-mapping tools. We called SNP genotypes and 4-digit classical HLA alleles in 2,198 fully sequenced genomes (Methods). We identified SNPs in tight linkage disequilibrium (LD) with the Late-Spike HLA-DQB1 classical alleles, that together represent what we henceforth call the Late-Spike haplotype (Methods). While most of the SNPs in highest LD with this haplotype (r ≥ 0.98) were within the HLA-DQB1 gene (89%), only six were intergenic ( fig. S14A ). An eQTL analysis in the 24 individuals of our initial cohort ( Fig. 1 ) confirmed that these 6 intergenic SNPs explained 76% of HLA-DQB1 expression variance at 72 hours (P = 3.8e-08, fig. S14B ). We assayed and identified open chromatin regions with ATACseq in memory CD4 + T cells after 72 hours of stimulation (Methods). In the HLA-DQB1 locus, the highest peak was located at the promoter and overlapped with SNP rs71542466 (Fig. 3C, fig.  S15 ). From published ChIP-seq data, this SNP overlapped promoter and enhancer associated chromatin marks in primary memory CD4 + T cells ( Fig. 3C) (22) , as well as binding peaks for HLA class II regulators: RFX5 (23) (in LCLs) and the co-activator CIITA (24) (B cells; fig S15) .
We hypothesized that amongst the 6 intergenic SNPs of the Late-Spike haplotype, rs71542466 located 39bp from the transcription start site of HLA-DQB1 is causal. To test this, we employed CRISPR/Cas9 editing in the HLA class II expressing T cell line, HH (Methods). First, we designed guide RNAs to cut near the 6 SNPs (fig. S16A) in order to assess the regulatory potential of each region. We observed that only editing near rs71542466 caused a significant decrease in HLA-DQ expression ( Fig. 3D, fig. S16B ). Next, we applied targeted base-editing to rs71542466 in order to convert the reference C allele to the alternative G allele. We predicted that HH T cell line clones homozygous for the rs71542466 reference allele should have lower HLA-DQB1 expression than base-edited clones with the alternative allele. We identified 7 clones homozygous for the alternative G allele, 7 clones homozygous for the reference C allele, and one clone with a 104bp deletion (fig. S17). As predicted, HLA-DQB1 was higher in alternative clones as measured by real-time PCR (P = 0.003, Fig. 3E ). We also noted that after extended culture, surviving alternative allele clones had higher expression of HLA-DQ protein as measured by flow cytometry (P = 0.03, Fig. 3E ). These results confirmed that the rs71542466 promoter SNP changes HLA-DQB1 expression in the expected direction in HH T cell lines, indicating that it at least partially accounts for the Late-Spike cis regulatory program.
After identifying the causal regulatory variant driving condition-dependent HLA-DQB1 expression, we considered whether this effect is T cell-specific. We observed that our Late-Spike regulatory rs71542466 SNP (rSNP) was not in LD with reported eQTL SNPs for HLA-DQB1 in B cell derived lymphoblastoid cell lines (LCLs), monocytes, and resting and infected macrophages (Table S2 , r 2 ≤0.27) (5, 8, (25) (26) (27) . In fact, our rSNP had no association with expression of HLA-DQB1 in resting macrophages (P = 0.81), in macrophages infected with Listeria (P = 0.31) or with Salmonella (P = 0.86) (27) .
To confirm the function and specificity of the Late-Spike rSNP, we applied luciferase assays and Electrophoretic Mobility Shift Assays (EMSA) in three cell-lines; HLA-DQ negative Jurkat E6-1 T cells, and HLA-DQ positive HH T cells and Daudi B cells ( fig. S18 ). EMSAs showed that only HH T cells had an allele specific band; we observed binding of nuclear extract proteins for the reference (C/C) but not the alternative (G/G) allele (Fig. 3F, fig. S19 ), suggesting that a repressor complex may bind to prevent upregulation of HLA-DQB1. Consistent with the base editing experiments, luciferase assays showed an increase in luminescence in the alternative (G/G) allele in HH T cells but not in Daudi B cells ( Fig. 3G) . Additionally, we stimulated primary B cells from the 5 homozygous individuals for the Late-Spike alleles and 5 homozygotes for the Fluctuating or Constant-Low alleles and did not observe fold change differences in HLA-DQ cell surface expression at 24 hours (P = 0.3, Wilcoxon test, fig. S20 ).
Intriguingly, within the HLA, dynamic gene regulation was not unique to HLA-DQB1. We observed dynASE in 5 other HLA genes. Within HLA class II genes, HLA-DRB1 had significant dynASE in 9 individuals (P < 2.1e-03, Bonferroni threshold), and HLA-DQA1 in 6 (P < 2.2e-03, Bonferroni threshold). Within HLA class I genes, HLA-B and HLA-C had significant dynASE in 12 individuals (P < 2.4e-03 and P <2.5e-03, Bonferroni threshold, respectively), and HLA-A in 6 (P < 2.2e-03, Bonferroni threshold). However, for these 5 genes, the magnitude of change in allelic fraction across time was more modest than for HLA-DQB1 ( fig. S21 ). We observed that in a subset of Late-Spike HLA-DQB1 haplotypes, the HLA-DRB1 allele that is in phase on the same chromosome also followed a Late-Spike pattern of expression ( fig. S22A ). This suggests potential promoter interactions between HLA-DQB1 and HLA-DRB1, consistent with promoter capture HiC data (fig. S22B) (28, 29) .
We found that 31 of our dynASE genes outside of the MHC were within autoimmune disease loci, including UBASH3A and IL10 (Fig. 4D ). We evaluated whether dynASE genes were significantly enriched in autoimmune disease loci using a stringent strategy where we compared the number of dynASE genes observed within risk loci and those found in 1000 null sets of loci across the genome (Methods). We found that dynASE genes are significantly enriched for risk loci for ankylosing spondylitis (OR = 5.7, P = 0.008), celiac disease (OR = 5.4, P = 0.004), vitiligo (OR = 5, P = 0.004), type 1 diabetes (OR = 4.5, P = 0.002), inflammatory bowel disease (OR = 3.7, P = 0.001), rheumatoid arthritis (OR = 3.6, P = 0.005), and multiple sclerosis (OR = 3.1, P = 0.003), but not for non-immune mediated diseases ( Fig. 4E) . We compared these enrichments to non-dynASE events prior to stimulation (those with ASE at 0 hours only) and to published eQTLs for resting CD4 + naïve T cells (8) . We observed that our dynASE genes, spanning up to 8 different cellular states, had the highest enrichment for autoimmune disease genes ( Fig. 4F) . We found similar results when we assessed enrichment of polygenic heritability in the regions around these genes versus the rest of the genome using stratified LD score regression ( fig. S23 ).
In this study, we showed that allelic imbalance in expression is highly context-dependent and very sensitive to the time after stimulation of memory CD4 + T cells. In most cases, there was a dominant allele that gradually increased or decreased its expression dominance with time (e.g. UBASH3A, CXCR5). We suspect that these cases are a consequence of a single regulatory complex interacting with a single genetic variant altering gene expression; where the status of the regulatory complex may vary dependending on the environmental context. However, in many instances, we observed that the allele that was dominant switched over time (e.g. HLA-DQB1, F11R), which raises the possibility of multiple regulatory variants or complexes. For example, we identifed distinct driving variants for HLA-DQB1 at 0 and 72 hours after stimulation (LD r 2 =0.01, Table S2 ). Overall, this widespread dynamic allelic imbalance across the genome illustrates the continuously changing regulatory landscape of genes during T cell activation.
We found that dynASE genes were highly enriched in autoimmune disease loci. This indicates that for many autoimmune disease genes, the risk allele may affect the expression of its target gene under very specific conditions. Indeed, this has already been shown for an autoimmune risk variant in an enhancer regulating IL2RA that affects its expression in a time-dependent manner, and the delay of expression by the risk allele leads to a preferential polarization of T cells into an inflammatory subtype (Th17) instead of the regulatory population (Treg) (30) . These results may explain why investigators have found limited shared genetic effects between autoimmune susceptibility variants and eQTL variants at resting state (3, 7, 31) , despite the presence of autoimmune susceptibility variants in regulatory elements (1-3, 32).
Intriguingly, we identified the most dramatic T cell and condition dependent cis regulatory variation within a major autoimmune disease gene: HLA-DQB1. This raises the question of whether, and to what extent, genetic regulatory variation controlling HLA gene expression could affect disease susceptibility or disease penetrance, as has been highlighted for other loci and traits (33) . For most autoimmune diseases, the MHC region is the major contributing locus to disease risk. We and others have shown that specific amino acid changes in the peptide binding grove of HLA-DQB1 and HLA-DRB1 explain the majority, albeit not all, of the risk assigned to the MHC region in T1D and rheumatoid arthritis (12, 34) . In this study, three of the four Late-Spike HLA-DQB1 classical alleles are protective for T1D (OR 0.045-0.732), while the other two regulatory programs represent a mixture of risk and protective alleles (12) . Detailed analyses on large sample sizes will be needed to disentangle the regulatory effects from the strong amino acid effects. While amino acid changes causing differential antigen display may be the primary autoimmune mechanism at the HLA locus, our data underscores the possibility that expression levels of HLA class II may also play a crucial and unappreciated role (35, 36) . Over the past several decades, there has been literature suggesting variation in expression among different HLA alleles (26, (37) (38) (39) -but to date the idea that this regulation changes with cell-state has not been established. It is well known that positive selection has resulted in dramatic coding variation within most HLA genes. Our results suggest that the same positive selection may also have favored regulatory variation in HLA-DQB1 and other HLA genes.
Broadly, class II expression has been well-characterized as a marker for both late activation in CD4 + T cells and suppressive capacity in T regulatory cells (40) (41) (42) . However, the exact mechanisms and functional implications remain to be defined. Our work shows that not only do CD4 + T cells express high levels of HLA Class II, but that its expression is regulated in a celltype specific manner and varies between individuals. This suggests that during immune responses, expression of HLA II on CD4 + T cells is dynamically controlled and may be important to modulating function.
Overall, by using both computational and experimental tools, we identified and validated highly context-specific genetic regulatory effects in stimulated memory CD4 + T cells and confirmed a causal variant in a key autoimmune gene. This work provides a framework for future studies to identify and validate relevant disease genes and variants.
Methods

Study design
The goal of this study was to characterize cell state-dependent regulatory effects in memory CD4 + T cells to obtain new insights into autoimmune disease mechanisms. In initial experiments, we observed the most dramatic dynamic allele-specific expression effects in HLA-DQB1. To investigate this phenomenon in an optimal way, we recruited individuals heterozygous for common HLA-DQB1 classical alleles (characterized by a combination of coding single nucleotide alleles), with highly divergent alleles (at least a 20 mismatch differences between the two alleles). We used the de-identified genome-wide genotypes available from the individuals at the Genotype and Phenotype (GaP) Registry at The Feinstein Institute for Medical Research, to impute HLA classical alleles with SNP2HLA (43) and select individuals. The GaP Registry provided de-identified cryopreserved PBMCs from 24 donors with no autoimmune disease, 20-50 years old, and of European ancestry. Donors provided fresh, de-identified human peripheral blood mononuclear cells (PBMCs); blood was collected from subjects under an IRB-approved protocol (IRB# 09-081) and processed to isolate PBMCs. The GaP is a sub-protocol of the Tissue Donation Program (TDP) at Northwell Health and a national resource for genotypephenotype studies (44). HLA classical alleles were subsequently experimentally confirmed with HLA typing (see below).
Similarly, for the protein level validation experiments, we recruited through the GaP Registry individuals homozygous for HLA-DQB1 classical alleles pertaining to the Late-Spike regulatory program (N = 5) or other programs (N = 5). These individuals were also between 20 to 50 years old, with no reported autoimmune disease, and of European ancestry.
Memory CD4 + T cell stimulation time course
PBMCs were thawed and resuspended in pre-warmed complete RPMI (cRPMI) (RPMI 1640, supplemented with 10% heat inactivated FBS, and 1% non-essential amino acids, sodium pyruvate, HEPES, L-Glutamine, Penicillin & Streptomycin, and 0.1% β-mercaptoethanol). Memory CD4 + T cells were isolated by magnetic selection (Miltenyi, Memory CD4 + T cell Isolation Kit human). Cells were counted, washed in cRPMI, and resuspended at a concentration of two million cells per ml. One million cells per well were plated in sterile 48 well plates (Corning). The cells were rested at 37°C overnight. Twelve hours after the beginning of the rest marked the first time point, T = 0 hours. At this time, cells were spun down and resuspended in 350 µL of RLT lysis buffer (Qiagen) containing β-mercaptoethanol and stored in a sterile Eppendorf tube at -80°C. To the remaining wells, 500 µL cRPMI with human T-Activator CD3/CD28 Dynabeads (Gibco) were added to each well at a ratio of 2 cells : 1 bead. Cells were collected at 2, 4, 8, 12, 24, 48, and 72 hours after stimulation. Once all cell pellets were collected, resuspended in RLT and frozen, the mRNA was isolated using a RNeasy mini kit (Qiagen). RNA concentration was measured using Implen's cuvette based UV/Vis spectrophotometer. The purified RNA samples were stored at -80°C until submitted for sequencing at the Broad Institute in Cambridge, MA.
Library construction and RNA sequencing
Total RNA was quantified using the Quant-iT™ RiboGreen® RNA assay kit and normalized to 5 ng/µL. Following plating, 2 µL of ERCC controls (using a 1:1000 dilution) were spiked into each sample. An aliquot of 200 ng for each sample was transferred into library preparation which uses an automated variant of the Illumina TruSeq™ stranded mRNA sample preparation kit. Briefly, oligo dT beads were used to select mRNA from the total RNA sample followed by heat fragmentation and cDNA synthesis. The resultant cDNA was then dual-indexed by 'A' base addition, adapter ligation using P7 adapters, and PCR enrichment using P5 adapters. After enrichment, libraries were quantified using Quant-iT PicoGreen (1:200 dilution). After normalizing samples to 5 ng/µL, the set was pooled and quantified using the KAPA library quantification kit for Illumina sequencing platforms. The entire process was performed in 96well format and all pipetting performed by either Agilent Bravo or Hamilton Starlet.
Pooled libraries were normalized to 2 nM and denatured using 0.1 M NaOH prior to sequencing. Flowcell cluster amplification and sequencing were performed according to the manufacturer's protocols using either the HiSeq 2000 or HiSeq 2500. Each run used 101 bp paired-end reads with eight-base index barcodes. Data was de-multiplexed and aggregated using the Broad Picard pipeline. Libraries were sequenced at a mean depth of 41 million fragments (read pairs), median 37 million, and minimum 24 million fragments.
Gene expression analyses
We mapped reads to the hg19 reference genome with subread v1.5.1(45) (with parameters:u -Q -D 100000 -t 0 -T 4) and quantified expression levels using featureCounts (with parameters: -T 4 -Q 20 -C -s 2 -p -P -D 100000) and GENCODE (46) v19 annotation. We removed two outliers, one had >50% of PCR duplicates and <60% of reads assigned to genes, the other one had less than 19,000 genes detected and less than 98% of common genes detected (common genes are those detected in at least 95% of samples; fig. S4 ). We considered expressed genes with log2(tpm+1) > 2 in at least 20 samples. For PCA we took 1,070 genes with standard deviation > 1 and mean expression > 3 log2(tpm+1), we scaled gene to mean zero and variance one and performed PCA with the R (47) function prcomp . For gene clustering, we used k-means on the scaled mean expression per gene. Six clusters captured 70% of between group over total sum of squares; increasing k, the predefined number of clusters, had minor incremental improvements. Enrichment of MsigDB hallmarks v6.2 (48, 49) was performed with the enricher function of the R package clusterProfiler (50) .
Variant genotyping, imputation and filtering
Individuals were genotyped genome-wide using the Genome Screen Array (GSA) assaying 647K SNPs. For pre-imputation QC, we used plink v1.90b3w (51) to filter out variants with missing call frequencies greater than 0.05, Hardy Weinberg Equilibrium (HWE) threshold P < 1e-05, MAF 0.03, keeping a total of 339,333 variants. We imputed variants into the 1000 Genomes reference panel (52) using SHAPEIT v2.r837 (53) and IMPUTE2 v2.3.2 (54) . We filtered out variants with info score < 0.9, multiallelic, HWE threshold P < 1e-05, nonpolymorphic within our 24 individuals, and with MAF <1% in Europeans of the 1000 Genomes reference panel, and indels. This yielded a total of 5,144,453 SNPs. When selecting heterozygous SNPs per individual, we further required a genotype probability > 0.9; a total of ~1.5M heterozygous SNPs per individual remained.
Dynamic allele-specific expression analysis
We used subread v1.5.1 to align reads to the hg19 reference genome and filtered out reads with mapping quality < 10. We used WASP (55) to filter out reads that had mapping bias at heterozygous sites and to remove duplicates. For quantifying allele counts at heterozygous sites, we used GATK (56) v3.8 ASEReadCounter (with parameters --minMappingQuality 10, --minBaseQuality 10, -U ALLOW_N_CIGAR_READS), and followed recommended best practices (57) . For initial QC ( fig. S6 ), for each sample we took all heterozygous sites with at least 10 reads (6,496-44,864 sites per sample). The mean coverage across sites per sample ranged from 50-127. All samples had >95% of both alleles observed at included heterozygous sites. The mean reference fraction was close to 0.5 for all samples (mean 0.5098, range from 0.5045 to 0.5159). For a given heterozygous site, the reference fraction refers to the number of reads with the reference allele divided by the total number of reads overlapping the site. Allelic imbalance is the distance to 0.5 reference fraction (i.e. absolute value of: the reference fraction minus 0.5).
To identify sites with dynamic ASE, we used a nested approach using a logistic regression framework on a per individual, per heterozygous site basis, with the lme4 (58) R package. Each read is encoded according to the following: 1 if it contains a reference allele or 0 if it contains the alternative allele. For each time course per individual, we included sites with at least 20 reads in at least 4 time points and required that both reference and alternative alleles are seen in all included samples. First, we identified sites with evidence of ASE by merging data from all time points and testing if the intercept is significantly different from zero (assuming a standard normal distribution and using a z-test) and used a Bonferroni threshold to determine significance (0.05 divided by the number of tests). Then, we tested which of these sites had ASE that changes with time by fitting a second order polynomial model, coding time point 1 through 8 (or maximum number of time points) and scaling to mean zero variance one. We controlled for overdispersion of allelic counts due to technical or biological sample to sample variability (59) by incorporating a random intercept effect, coding sample ID as a factor. We tested for the effects of time by performing a likelihood ratio test between the two nested models using R anova function. The null model H 0 and alternative model H 1 for a given SNP i in a given individual j are detailed below:
Where ! is the probability of observing the reference allele, α is the intercept, µ is the random intercept effect across samples, t is time, and β is the effect of time on the log-odds of observing the reference allele. We calculated the FDR per test using the qvalue R package (60) , and called significant all events with q<0.05 (<5% FDR), unless otherwise stated.
Functional enrichment for dynASE genes was performed using the C5 genesets from MsigDB, which are composed of GO biological processes (c5.bp.v6.2). Enrichment with respect to all tested genes or all genes with significant ASE (over all merged time points) was tested with the enricher function, of the clusterProfiler R package, which is based on the hypergeometric distribution.
HLA typing
Purified DNA from the 24 individuals was sent to the NHS Blood and Transplant, UK, where HLA typing was performed. Next generation sequencing was done for HLA-DQB1, HLA-A, HLA-B, HLA-C, and for HLA-DRB1. PCR-SSOP was done for HLA-DQA1 in all individuals, and for HLA-DRB1 in 6 individuals for which limited DNA was available. These typing methods yielded classical allele calls for the six genes at 4 to 8-digit resolution.
Allele-specific expression in HLA genes
To prepare an HLA personalized genome for each individual we first took the HLA 6-digit classical allele calls for each of the 6 HLA genes (12 alleles total) and downloaded from the IPD-IMGT/HLA database (61) the corresponding cDNA sequence. Next, we added the 12 cDNA sequences to the hg19 reference genome, each encoded as a separate chromosome. We masked with Ns the exonic regions corresponding to the cDNA sequences. We indexed the genome for subread usage.
For each individual, we aligned per sample the reads to the HLA-personalized genome with subread (with parameters: -u -Q -D 100000 -t 0 -T 4). We removed PCR duplicates with Picard Tools v1.119. We counted the number of uniquely mapped reads to each HLA allele with featureCounts (with parameters: -T 4 -Q 40 -p) using a personalized gtf annotation file per individual.
To identify dynASE for each HLA gene, we used the same statistical approach mentioned above. Instead of using allele counts for a single SNP, we used counts for the whole cDNA per HLA allele (usually encompassing 3-4 exons, 552-1119 bp). To compare HLA allelic expression levels between samples, we normalized the HLA allele counts by library size and cDNA size (FPKM). For the two individuals for which we had full time course replicates, we used the mean of the FPKM values.
For testing whether allelic profiles of HLA-DQB1 4-digit classical allele groups are more similar to each other than expected by chance, we calculated the sum of squares within 4-digit allele groups, and total sum of squares (observed values). Then, we permuted the 4-digit allele groups 10,000 times, and repeated the sum of squares calculations ( fig. S10 ). For this analysis, we excluded four allelic profiles with 4-digit alleles that were present only once in our 48 allelic profiles (DQB1*04:02, DQB1*06:01, DQB1*06:09 and DQB1*05:03).
For HLA-DQB1 allelic profile grouping with k-means clustering and PCA, we removed the 12 hour time point due to its high number of missing values (caused by an insufficient number of cells obtained for some individuals), and further excluded another 2 individuals with missing values, resulting in a total of 44 allelic profiles (2x22 individuals). For both of these analyses we used log2(FPKM+1) values. Three clusters captured 64% of the variation in our data, defined by the ratio of between group sum of squares and total sum of squares. Two clusters captured a significantly lower amount of between group variability (37%), and four clusters (70%) had a modest increase from three. PCA was performed on allelic expression profiles with prcomp with center = TRUE, and independently showed that the three clusters identified with k-means separate well ( fig. S11 ).
HLA-DQ protein level validations on memory CD4 + T cells and B cells
Ten additional individuals were recruited through the GaP Registry (see Study Design). Five individuals were homozygous for Late-Spike alleles: one for DQB1*05:03 and four for DQB1*05:01. Five individuals were homozygous for alleles in the other two cis regulatory programs (Constant-Low, and Fluctuating): one for DQB1*03:02, one for DQB1*02:01, one for DQB1*02:02 and two for DQB1*03:01. PBMCs were thawed and put immediately in warm cRPMI. For analysis of memory CD4 + T cells, cells were washed twice and isolated as before using a magnetic selection kit (Miltenyi, Memory CD4 + T cell Isolation Kit human). Isolated cells were then rested overnight at a concentration of 1 million/mL in 48 well plates and stimulated the next day with anti-CD3/CD28 dynabeads at a ratio of 2 cells:1 bead. T cells were assayed for expression of HLA-DQ by flow cytometry on day 0 (unstimulated) and days 1, 3, and 7. For all samples, cells were isolated, washed twice in PBS, and stained with Zombie Violet Live/Dead (Biolegend) for 30 minutes on ice. After staining, cells were washed and Fc receptors blocked with FcX True Stain (Biolegend) for 15 minutes on ice followed by staining with directly conjugated antibodies: PE anti-HLA-DR (Biolegend, Clone: L243), APC anti-HLA-DP(Leinco Technologies, Clone: B7/21), FITC anti-HLA-DQ(Biolegend, Clones: HLADQ1 or Tu169), BV711 anti-CD25(Biolegend, Clone: M-A251), and PE-Cy7 anti-CD4(Biolegend, Clone: OKT4). Cell were stained for 30 minutes on ice, washed twice, and samples analyzed on a BD LSR Fortessa. For B cells, 0.5 million total PBMCs in cRPMI were stimulated with a cocktail of CpG (2006, 0.35 µM), CD40L (1 µg/mL), anti-Ig (10 µg/mL), and rhIL-21 (20 ng/mL) in 48 well plates for 0 and 1 day. As before, all samples were isolated, stained with Live/Dead, and Fc receptors blocked. Cells were then stained for 30 minutes on ice with PE anti-HLA-DR (Biolegend, Clone: L243) , APC anti-HLA-DP (Leinco Technologies, Clone: B7/21), FITC anti-HLA-DQ (Biolegend, Clones: HLADQ1 or Tu169), PeCy7 anti-IgD (Biolegend, Clone: IA6-2), BV510 anti-CD27 (Biolegend, Clone: O323), BV605 anti-CD3(Biolegend, Clone: OKT3), BV785 anti-CD38 (Biolegend, Clone: HB-7), BV650 anti-CD19(Biolegend, Clone: HIB19), PerCP-Cy5.5 anti-CD45R0 (Biolegend, Clone: UCHL1), BUV496 anti-CD4 (BD Biosciences, Clone: SK3). As before, data was collected on a BD LSR Fortessa. All data was processed using Flowjo, gated as shown in the supplement, and channel values exported for analysis.
Regulatory variant fine-mapping
To look for genetic variants in LD with the Late-Spike haplotype, we called Single Nucleotide Variants (SNVs), small INsertions and DELetions (INDELs) and classical HLA variants using whole genome sequences of 2,244 healthy volunteers recruited from the Estonian Genome Project (62, 63) sequenced at 25x. We performed high-resolution (G-group) HLA calling of three class-I HLA genes (HLA-A, -B and -C) and three class-II HLA genes (HLA-DRB1, -DQA1 and -DQB1) using the HLA*PRG algorithm (64) . We called SNVs and INDELs using GATK version 3.6 according to the best practices for variant discovery (65) . In total we called 246,505 variants in the extended MHC region (29-34 Mb on chromosome 6, NCBI Build 37).
To check if any SNVs are in high LD with the Late-Spike haplotype, we first used the Estonian reference panel and restricted our analyses to individuals who carried the alleles present in our 24 individuals (N = 2,198). Namely, there were 58 individuals with two HLA-DQB1 alleles (at 4-digit resolution) pertaining to the Late-Spike haplotype (i.e. DQB1*05:01, 05:02, 05:03 or 06:01), 616 with one Late-Spike haplotype allele, and 1,524 individuals with zero Late-Spike haplotype alleles. To filter out possible false-positive variants, we next restricted the analyses to SNPs with minor allele frequency (MAF) ≥ 0.05 and within 1 Mb region of the HLA-DQB1 gene (N = 27,210). Next, we computed the Pearson correlation between Late-Spike haplotype dosage (0, 1 or 2) and individual SNP genotypes. Refseq gene annotations were used to determine start and end of HLA-DQB1, HLA-DRB1 and HLA-DQA1.
For the eQTL analyses within our cohort we used log2(FPKM+1) gene expression values for HLA-DQB1 (the sum of FPKM of both alleles from each individual) at a given time point and looked for association of expression with SNPs (with MAF 5%) within 1Mb of the TSS using Pearson correlation.
ATAC-seq experiments and data processing
Memory CD4 + T cells from one new PBMC donor from the GaP Registry were purified and cultured as described above for 72 hours with anti-CD3/CD28 stimulation beads. Post stimulation, the cells were harvested and washed with PBS. Cells were then resuspended in 500µL of a freshly prepared 1% formaldehyde solution (Thermo Scientific) and fixed for 10 minutes. The fixation reaction was subsequently quenched with the addition of 2.5 M glycine for 5 minutes. The sample was spun to remove the fixative and washed in PBS. The solution was carefully decanted and the resulting pellet was frozen. For open chromatin library preparation, two samples, one of 50,000 cells and another of 10,000 cells, were resuspended in 1 mL of cold ATAC-seq resuspension buffer (RSB; 10 mM Tris-HCl pH 7.4, 10 mM NaCl, and 3 mM MgCl 2 in water). Cells were centrifuged at max speed for 5 min in a pre-chilled (4°C) fixed-angle centrifuge. After centrifugation the supernatant was carefully aspirated. Cell pellets were then resuspended in 50 µL of ATAC-seq RSB containing 0.1% NP40, 0.1% Tween-20, and 0.01% digitonin by pipetting up and down three times. This cell lysis reaction was incubated on ice for 3 min. After lysis, 1 mL of ATAC-seq RSB containing 0.1% Tween-20 (without NP40 or digitonin) was added, and the tubes were inverted to mix. Nuclei were then centrifuged for 5 min at max speed in a pre-chilled (4°C) fixed-angle centrifuge. The supernatant was removed and nuclei were resuspended in 50 µL of transposition mix (66) 2.5 µL transposase (100 nM final), 16.5 µL PBS, 0.5 µL 1% digitonin, 0.5 µL 10% Tween-20, and 5 µL water) by pipetting up and down six times. Transposition reactions were incubated at 37°C for 30 min in a thermomixer with shaking at 1,000 rpm. Reactions were cleaned up with Qiagen columns. Libraries were amplified as described previously (67) .
Libraries were paired-end sequenced with an Illumina NextSeq 500 with read length of 150 bp. Reads were mapped to the hg19 reference genome with subread. Uniquely mapped reads with mapping quality > 10 were selected, and PCR duplicates were removed with Picard tools. Peaks on chromosome 6 were called with MACS2 (with parameters --nomodel -q 0.1).
Cell lines
HH cutaneous T cell lines (ATCC: CRL-2105), Jurkat E6-1 (ATCC: TIB-152), and Daudi (ATCC: CCL-213, provided by Dr. Michael Brenner), were all cultured in complete RPMI as previously described.
Bulk CRISPR/Cas9 editing
To investigate regulatory regions around HLA-DQ, the nearest sgRNA to the SNP of interest was selected using Deskgen online tools (www.deskgen.com). Distances of designed sgRNA to the nearest SNP are shown in fig. S16 . To confirm the sequence of the region, genomic DNA around HLA-DQB1 was PCR amplified and Sanger sequenced using the primers: 5'-TCGGGTCTCTGAATCCCACT & 5'CAGGACCCAGGAAATGCTTCT, and 5'GGAGCTCTGCCATTTGTCCT & 5'TGACTCTGCTTCCTGCACTG. CRISPR/Cas9 RNP complexes were assembled as previously described (68) . Briefly, 40 µM Cas9 protein (QB3 Mircolabs) was mixed with equal volumes of 40 µM modified sgRNA (Synthego) and incubated at 37°C for 15 minutes to form ribonuclear protein (RNP) complexes. HH cells were nucleofected with 2µL of RNPs in an Amaxa 4D nucleofector (SE protocol: CL-120). Cells were immediately transferred to 24 well plates with pre-warmed media and cultured. After 7-10 days, HLA-DQ expression was assessed by flow cytometry. Editing was confirmed by PCR amplifying genomic DNA around HLA-DQB1 and sequences analyzed by Tracking of Indels by Decompostiion (TIDE) analysis (tide.deskgen.com).
sgRNA target sequences with PAM bolded rs28451423 -TGTGAAATCAACTTGACTCTAGG, rs71542466 -GCTGATTGGTTCTTTTCCGAGGG, rs72844401 -AATGCCTCGGGGATTTTGAGAGG, rs4279477 -AGAACTTTGCTCTTCTCCCCAGG, rs71542467 -GAGCTGAAGAACGAATGCCTCGG, rs71542468 -GCTGAAGAACGAATGCCTCGGGG
CRISPR/Cas9 base-editing of rs71542466 in HH cells
For generation of base-edited cell lines, HH cells were nucleofected with RNPs using sgRNA targeting near rs71542466 and asymmetrical ssDNA donors as previously described (69) . Modified cells were grown for 7-10 days then single cell sorted using a BD Aria II into 96 well U bottom plates. After 2-3 months of outgrowth, DNA from surviving clones (194/1200) was isolated using DNA quick extract solution (Lucigen) following a modified protocol. Briefly, 100 µL of cell culture was spun down, washed once with PBS, and then re-suspended in 20 µL of DNA extraction solution. Solution was heated in a thermocycler to 65°C for 15 minutes, 68°C for 15 minutes, 98°C for 10 minutes, and stored at 4 degrees. After DNA extraction, solution was diluted 1:20 and 5 µL used in a standard 50 µL PCR reaction using Q5 enzyme (NEB). PCR products were Sanger sequenced and analyzed using SnapGene to identify SNP corrected clones (7/192), wildtype HH clones (7/192) , and a single (1/194) insertion / deletions clone. Sequences are shown in fig. S17 .
HDR sequence ACAGCTCGGACCTGATGGATCTGATGTACCTGGCAGAAAGAATAAAAACCTG TGGATGTTTCCGTGAGTGGCAGGATTGGATGGTCGCTCGGAAAAGAACCAATCAG CACTGGAGCTGAAGGACCTC
Real-time PCR and flow cytometry analysis of HH clones
For analysis of HLA-DQB1 expression on HH WT (C/C) and ALT (G/G) clones, RNA was extracted from clones using a Monarch Total RNA extraction kit (NEB). cDNA was synthesized using MaximaH RT (NEB) enzyme following manufacturer's protocol and oligoDT primers. cDNA was diluted 1 in 4 with HLA-DQB1 (Assay ID:Hs00409790) and actinB (Assay ID:Hs01060665) probes and Taqman MasterMix (Thermofisher). Samples were run on an ARIAmx qPCR machine (Agilent) and data analyzed with Aria 1.5 (Agilent) software. Expression is represented as 2 -delta(HLA-DQB1 Ct -ActinB Ct) . For analysis of protein expression, clones that survived after 3-4 months of culture were washed with PBS and stained with FITC anti-HLA-DQ (Biolegend, Clone: HLADQ1) for 30 minutes on ice and cell surface expression assessed by flow cytometry. Data was analyzed using Flowjo and Graphpad PRISM.
Electrophoreitc Mobility Shift Assays
EMSAs were performed using the LightShift Chemiluminiscent EMSA Kit (Thermo Scientific). Single-stranded biotinylated oligonucleotides and complementary sequences corresponding to 31 nucleotides (15 nucleotides flanking the SNP of interest) were purchased from Eurofin Genomics and annealed by heating at 95°C for 5 minutes followed by a ramp down (-1°C/ minute) to room temperature (20°C).
Nuclear extract from Jurkat, HH, and Daudi cells was isolated using the NE-PER nuclear and cytoplasmic extraction kit (Thermofisher Scientific) with slight modification. 20 million cells were spun down, washed twice with PBS, and used in the protocol with half volumes of NER buffer. All buffers contained protease inhibitors (Thermofisher). Protein extracts were then dialyzed using a membrane with a molecular weight cut-off of 12-14 kDa (Spectrum Spectra) against 1 L of dialysis buffer (10 mM Tris pH 7.5, 50 mM KCl, 200 mM NaCl, 1 mM dithiothreitol, 1 mM phenylmethane sulfonyl fluoride, and 10% glycerol) for 16 h at 4°C with slow stirring. The protein concentration was measured using the Pierce BCA protein assay kit (Thermo Scientific).
The standard binding reaction contained 2 µL of 10× Binding Buffer, 2.5% glycerol, 5 mM MgCl2, 0.05% NP40, 50 ng Poly(dI:dC), 20 fmol biotin-labeled probe, and 10-20 µg of nuclear extract in a final volume of 20 µL. For competition, a 200-fold molar excess (4 pmol) of unlabeled probe was added.
Binding reactions were incubated at room temperature for 30 min and loaded onto a 6% polyacrylamide 0.5× Criterion precast TBE gel (Biorad). After sample electrophoresis and transfer to a nylon membrane, DNA was crosslinked for 10 min, and biotinylated probes detected by chemiluminescence followed by film exposure. Original films and replicated are presented in a fig. S19 .
List of probes: Alt
Luciferase assay A double-stranded oligonucleotide containing the SNP of interest (31nt + restriction enzyme sites) was ordered and annealed as described above. Probes and the luciferase reporter vector pGL3 promoter (Promega) were digested with BglII (NEB) for 1 h at 37°C, and the linearized vector was simultaneously dephosphorylated with alkaline phosphatase (NEB). Digestion products were purified with the Gel Extraction Kit (Thermofisher) from 1% agarose gels. Ligation was then performed in a ratio of 1:50 (vector:insert) with T4 DNA ligase (NEB) at room temperature for one hour and then transformed into NEB10 competent cells (NEB). Plasmids from independent colonies were isolated using a plasmid DNA minikit and Sanger sequenced to identify correctly inserted clones.
3 × 10 5 Jurkat, HH, and Daudi cells were nucleofected with 0.9 µg of pGL3-Promoter vector along with 0.1 µg of pRL-TK Renilla luciferase vector (Promega) in 16 well strips in a 4D nucleofector with the following protocols and buffers in 20 µL of total volume: Jurkat, SE buffer, CL-120 protocol; HH, SE buffer, CL-120 protocol; Daudi SF buffer, CA-137 protocol. After nucleofection, 180 µL of complete RPMI was added and cells cultured in 96 well flat bottom plates (Falcon). After 48 hours, cells were spun down, resuspended in 75 of fresh complete media, and luciferase/renilla activity measured using the Dual-Glo Luciferase Assay System (Promega). Firefly luciferase activity was expressed as relative luciferase units (RLU) after correction for Renilla luciferase activity. Data were normalized to those cells transfected with empty pGL3-Promoter vector. Each dot represents an independent nucleofection reaction.
Autoimmune disease enrichment analyses
We downloaded SNPs from the GWAS catalogue on July 17, 2018. We selected SNPs with P < 5e-08 for 11 autoimmune diseases and 3 non-immune mediated diseases that served as a negative control (schizophrenia, type 2 diabetes, coronary heart disease). We used SNPsea to capture genes within disease loci based on LD and recombination interval information (70) . We then assessed how many of the dynASE genes overlap genes in disease loci for each disease (observed overlap). To assess whether this overlap represented a significant enrichment, for each disease we created 1000 null sets of N random regions in the genome (N = number of disease loci), which were matched by the number of genes per locus (within 15% of each disease locus). We then calculated the ratio of observed overlap with the mean overlap of our 1000 null sets (fold enrichment). We calculated the P-value as: (number of null overlaps larger than observed overlap + 1)/1001 (71) . We took the same approach for genes with significant ASE at 0 hours (N = 501), and eQTL genes of naïve T cells reported by the Blueprint Consortium (N = 5,688) (8) .
We carried out a heritability enrichment analysis using GWAS summary statistics and stratified LD score regression (S-LDSC) (32) for six autoimmune diseases and three non-immune mediated diseases. For each gene category described above (dynASE, 0 hours ASE, naive T eQTL), we separately created functional annotations consisting of all SNPs within +/-100 kb of each gene. We define enrichment of an annotation as the proportion of heritability explained by the annotation divided by the proportion of the common (MAF ≥ 0.05) SNPs included in the annotation. To test for enrichment significance, S-LDSC tests if the per-SNP heritability is greater in the functional annotation than outside of the functional annotation. Standard errors around the enrichment mean are computed by using a block jackknife of 200 equally-sized adjacent blocks of SNPs genome-wide. Then, we compute a z-score to test for significance.
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